Indicated for: asthma; chronic obstructive pulmonary disease
Substance: salmeterol + fluticasone (beta-2 adrenergic agonist + glucocorticoid)
ATC: R03AK06 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)
Salmeterol+fluticasone is a combination medication used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol is a long-acting beta-2 adrenergic agonist that relaxes airway muscles and improves airflow. Fluticasone is an inhaled corticosteroid that reduces inflammation and prevents exacerbations.
This combination is administered via inhalation, usually twice daily, and is indicated for patients requiring both bronchodilation and anti-inflammatory control. It is effective in reducing symptoms, preventing asthma attacks, and improving quality of life.
Common side effects include throat irritation, hoarseness, oral fungal infections (candidiasis), and tremors. In rare cases, severe adverse reactions such as paradoxical bronchospasm or adrenal suppression may occur. Patients are advised to rinse their mouth after use to reduce the risk of candidiasis.
Salmeterol+fluticasone is a valuable therapeutic option for patients with chronic respiratory conditions, providing effective symptom control and prevention of exacerbations.